Milan
Facility

Equipment & Technology

• GMP / Quality Control (QC)

  • Two site locations with 230+ experts in Milan & North Milan

  • Three streams for 24L/48L lentiviral and retroviral vector manufacturing in cell factories

  • One stream for 200L lentiviral and retroviral vector manufacturing in a fixed-bed bioreactor

  • Nine Class B suites for engineered cells manufacturing and MCB/WCB/PPCB generation, equipped with cell enrichment/cell washing/cell expansion automated machines

  • One Class B suite for autologous/allogeneic genetically modified T-cells manufacturing

  • One Class C suite for automated fill & finish

  • One Class C suite for media preparation

  • >35 labs in QC area for product testing and release

• Development Area

  • Areas for small-, medium- and full-scale manufacturing of lentiviral and retroviral vectors, equipped with several small-scale fixed-bed bioreactors and stirred-tank bioreactors for upstream manufacturing and 4 different liquid chromatography systems and three different TFF systems for downstream processes

  • Areas for small-, medium- and large-scale engineered cell manufacturing, equipped with cell enrichment, cell washing and cell expansion automated machines 

  • Areas for analytical method development and qualification, including automated liquid handling systems

• Ongoing Expansion

  • We're dedicated to continuous innovation, and as such, we constantly invest heavily in new technology, new modalities and new and expanding facilities, to stay ahead of our customer’s ever-evolving needs.

  • In recently shared expansion plans, we announced that we will add two additional floors to the suite and install additional equipment on the current floor in the Milan facility. The new facilities are scheduled to begin full operation in 2022.

  • In addition to continuously enhancing and extending capabilities in Milan, we will be establishing significant cell and gene therapy offerings in Longmont by 2022.